Recent news on Zosyn

Pharma Sector: Few Newsmakers Of The Week - Ista, Wyeth, Bristol ...  -  May 12, 2007
Trading Markets,By the end of 2008, antibiotic treatment Zosyn, antidepressant Effexor and pneumococcal vaccine Prevnar would have lost patent exclusivity.

Wyeth profit rises 12%, helped by vaccine sales  -  Apr 19, 2007
MarketWatchWyeth said sales of Zosyn, the No. 1 selling IV antibiotic worldwide, reached $1 billion on an annual basis, and it has made "significant progress"

Wyeth Reports Earnings Results for the 2007 First Quarter  -  Apr 19, 2007
PR Newswire (press release),ZOSYN(R) retained its status as the number one selling IV antibiotic worldwide and reached $1.0 billion in its moving annual total in the 2007 first quarter

Wyeth Profit Up on Sales of Vaccine, Arthritis Drug (Update3)  -  Apr 19, 2007
BloombergZosyn, an antibiotic, junped 18 percent to $281 million. Revenue from the hormone-replacement therapies Prempro and Premarin fell 9 percent to $241 million.

Wyeth Q1 Profit Rises; Adj. EPS Tops Consensus - Update  -  Apr 19, 2007
Trading Markets,...up 11% over last year due primarily to higher sales of Prevnar, Enbrel, Nutrition products and Zosyn offset, in part, by lower sales of Effexor,

Superbugs driving blockbusters  -  Mar 7, 2007
Monsters and Critics.com,Zosyn, which is given intravenously for nosocomial lower-respiratory-tract infections, is growing at a very strong rate that is expected to continue until

3 cos sue Wyeth over Zosyn patent  -  Feb 2, 2007
Economic Times,Wyeth discontinued its original formulation for antibiotic drug Zosyn in November 2005 and subsequently launched a new version with a fresh patent,

Growth zone ahead  -  Feb 11, 2007
Economic Times,Tazobactum-Piperacillin (brand name Zosyn), which Orchid is likely to launch in the US, is expected to be a major growth driver in the short term.

Wyeth's Slow Growth  -  Jan 30, 2007
Motley FoolBy the end of 2008, key patents will have expired on its $1 billion-a-year antibiotic treatment Zosyn, $2 billion-a-year vaccine Prevnar, and almost $4

Wyeth may not launch depression drug until 2008  -  Jan 30, 2007
ReutersThe company also told analysts it does not expect a generic form of its antibiotic Zosyn to be launched in the United States until late 2007, if at all.

Prevnar, Enbrel and Effexor drive Wyeth growth  -  Jan 31, 2007
Pharma Times (subscription),Sales of the gastrointestinal drug Protonix (pantoprazole) were flat at $419.6 million, while Wyeth's Zosyn (piperacillin/tazobactam) antibiotic climbed 21%

Pharma Sector: Few Newsmakers Of The Week - Onyx, Mylan ...  -  Feb 18, 2007
Trading Markets,For Wyeth, which is set to lose patent protection on three of its top selling drugs (antibiotic treatment Zosyn with annual sales of $1 billion,

Wyeth Reports Earnings Results for the 2006 Fourth Quarter and ...  -  Jan 30, 2007
PR Newswire (press release),416.1 40% 1499.6 38% Alliance Revenue(1) 370.4 6% 1339.2 17% Nutritionals 306.7 20% 1200.8 15% Premarin Family 262.4 20% 1050.9 16% Zosyn/Tazocin 248.8

Analysis: Analysts split on Wyeth  -  Jan 30, 2007
Science Daily (press release)Zosyn sales were up 21 percent to $249 million, while Premarin/Prempro sales rose 20 percent to $262 million. Wyeth forecast 2007 EPS would be $3.40 to

Patent Expiries of Leading Antibiotics From Several Pharmaceutical ...  -  Jan 9, 2007
PR Newswire (press release),Sanofi-Aventis's Tavanic, Daiichi-Sankyo's Cravit, Merck's Primaxin, Abbott's Omnicef, AstraZeneca's Merrem, and Wyeth's Zosyn together generated more

Hospira stock slips after forecast cut  09 Nov 2006
Hospira Chief Executive Christopher B. Begley said Wyeth's reformulation of its antibiotic Zosyn will stop Hospira from bringing a generic version to the ... -Chicago Sun-Times, India top drug tweaker again  Aug 16, 2006
...in 2007. Aurobindo also filed for piperacillin, one of the active ingredients for Zosyn, which will also be expired in 2007. A few ... -Daily News & Analysis

Optimer Pharmaceuticals Appoints Kevin P. Poulos as Vice President ...  Aug 1, 2006
...activities of novel anti-infective classes and products such as Oxazolidinones (Zyvox(R)), Beta-lactamase inhibitor combinations (Zosyn(R)/Tazocin(R), Timentin ... -Genetic Engineering News

Wyeth Wins Again  Jul 20, 2006
...tradeoff in the coming years. The only major patent expiries coming up are Zoton in '06 and Zosyn in '07. And while these might ... -Motley Fool

Gatifloxacin-Induced Hallucinations in a 19-Year-Old Man  Jul 14, 2006
...on Hospital Day 4 showed no signs of improvement, so his antimicrobial coverage was increased by adding 3.375 g of piperacillin/tazobactam (Zosyn®) every 6 ... -Psychosomatics (subscription)



Novel antibiotic from Wyeth gets green light in Europe  May 3, 2006
Tygacil is a key element in Wyeth's strategy to extend its antibiotic franchise, which also includes Zosyn/Tazocin (piperacillin/tazobactam), the world's top ... - Pharma Times (subscription)





Uncle Sam vets the names of potential drugs  Mar 17, 2006
The other drugs were Zofran, an antinausea drug, and Zosyn, an antibiotic. Bob Lee, trademark counsel at Lilly, says he was surprised by the FDA's rejection. ... - Pittsburgh Post Gazette

Many drug names fail to pass FDA muster  Mar 19, 2006
...others used in critical care. The other drugs were Zofran, an antinausea drug, and Zosyn, an antibiotic. Bob Lee, trademark counsel ... - Sun-Sentinel.com



Wyeth "neutral weight," estimates reduced  Feb 2, 2006
...for 2007 has been raised from $3.25 to $3.37 to reflect the possibility of the company launching a new drug to eliminate the competition from generic Zosyn. - New Ratings

Wyeth upgraded to "buy" - update  Feb 3, 2006
...that the generic risk to the company has reduced until 2009/2010, with the Effexor XR patent settlement and the potential launch an improved version of Zosyn. ... - New Ratings

Wyeth "neutral weight," estimates reduced  Feb 2, 2006
...for 2007 has been raised from $3.25 to $3.37 to reflect the possibility of the company launching a new drug to eliminate the competition from generic Zosyn. - New Ratings

Merck, Wyeth Sales Rise Little as Demand Falls for Top Drugs  Jan 31, 2006
Wyeth had ``a slightly disappointing quarter'' because demand for Effexor and the antibiotic Zosyn was less than expected, said Prudential Equity Group analyst ... - Bloomberg

Wyeth Seen 'Finally Putting Fen-Phen Behind'  Feb 1, 2006
...billion. Reasons given for the slightly weaker-than-expected revenue were light sales of Effexor, Zosyn and Refacto, said Rubin. ... - Forbes

Wyeth Reports Earnings Results for the 2005 Fourth Quarter and ...  Jan 31, 2006
ZOSYN(R), a broad-spectrum IV antibiotic proven to help minimize the emergence of bacterial resistance, had net revenue of $205 million in the 2005 fourth ... - PR Newswire

Wyeth Reports Earnings Results for the 2005 Fourth Quarter and ...  Jan 31, 2006
ZOSYN®, a broad-spectrum IV antibiotic proven to help minimize the emergence of bacterial resistance, had net revenue of $205 million in the 2005 fourth ... - Yahoo! News

Merck, Wyeth Sales Rise Little as Top Drugs Slow (Update1)  Jan 31, 2006
Quarterly sales of Effexor were $841 million, down 1 percent, while sales of the antibiotic Zosyn rose 3 percent to $205 million. ... - Bloomberg

Wyeth upgraded to "buy" - update  Feb 3, 2006
...that the generic risk to the company has reduced until 2009/2010, with the Effexor XR patent settlement and the potential launch an improved version of Zosyn. ... - New Ratings

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional